Prelude Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Prelude Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-32,739	Closed	-$504K	–	1536
2025 Q3	$504K	Sell	32,739 -57,094	-64%	-$747K	0.04%	506
2025 Q2	$841K	Sell	89,833 -1,884	-2%	-$20.7K	0.08%	299
2025 Q1	$1.13M	Buy	91,717 +5,492	+6%	+$77.5K	0.09%	280
2024 Q4	$1.14M	Buy	+86,225	New	+$1.48M	0.07%	349
2023 Q2	–	Sell	-10,943	Closed	-$231K	–	1330
2023 Q1	$231K	Buy	+10,943	New	+$272K	0.01%	785
2020 Q4	–	Sell	-300	Closed	-$4K	–	1919
2020 Q3	$4K	Buy	+300	New	+$4.57K	﹤0.01%	1596
2018 Q2	–	Sell	-71,938	Closed	-$1.02M	–	1924
2018 Q1	$1.02M	Buy	71,938 +39,572	+122%	+$420K	0.07%	276
2017 Q4	$284K	Buy	+32,366	New	+$320K	0.02%	540
2017 Q2	–	Sell	-28,742	Closed	-$394K	–	1828
2017 Q1	$394K	Buy	+28,742	New	+$298K	0.04%	370

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Prelude Capital Management's SNDX Position: Q4 2025 in Review

Prelude Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 32,739 shares — an estimated $504K sold.

Prelude Capital Management first reported a position in SNDX in Q1 2017 and held it in 9 quarters. The position peaked at $1.14M in Q4 2024. 230 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

Prelude Capital Management reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Prelude Capital Management sold 32,739 Syndax Pharmaceuticals shares in Q4 2025, an estimated $504K.
Prelude Capital Management first reported a position in Syndax Pharmaceuticals in Q1 2017 and held it in 9 quarters.
Prelude Capital Management's Syndax Pharmaceuticals position peaked at $1.14M in Q4 2024.
230 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.